Manufacturing USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns BioSpaceAlmost half of the top 100 medicines vulnerable to supply disruptions in the U.S.ManufacturingRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) BioSpace Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S. ManufacturingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Allogene stock sails after CAR T clears residual lymphoma in early data cutNext: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results Related Stories Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026 Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026 Manufacturing GSK to quit Stevenage for new R&D site in Cambridge pharminent July 28, 2026
